Pages that link to "Q36985600"
Jump to navigation
Jump to search
The following pages link to Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects (Q36985600):
Displaying 50 items.
- Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors (Q24306212) (← links)
- Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions (Q26799387) (← links)
- Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity (Q27320733) (← links)
- Cancer despite immunosurveillance: immunoselection and immunosubversion (Q28263865) (← links)
- Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia (Q28477798) (← links)
- Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma (Q28584858) (← links)
- Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis? (Q33314413) (← links)
- Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha (Q33421740) (← links)
- Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission (Q33593877) (← links)
- Cutting Edge: MMP-9 inhibits IL-23p19 expression in dendritic cells by targeting membrane stem cell factor affecting lung IL-17 response (Q33777494) (← links)
- Dasatinib promotes Th1-type responses in granzyme B expressing T-cells (Q33930605) (← links)
- Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice (Q34012590) (← links)
- Dendritic cell c-kit signaling and adaptive immunity: implications for the upper airways (Q34015306) (← links)
- The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation (Q34015801) (← links)
- Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). (Q34028872) (← links)
- Immunological off-target effects of imatinib (Q34046541) (← links)
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial (Q34083140) (← links)
- Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis (Q34129408) (← links)
- Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo (Q34395057) (← links)
- Interactions between the intestinal microbiota and innate lymphoid cells. (Q34397537) (← links)
- Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. (Q34479264) (← links)
- Innate immune recognition and suppression of tumors (Q34550147) (← links)
- Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma (Q34586486) (← links)
- The role of mast cells in cancers (Q35029612) (← links)
- Cytokines reinstate NK cell-mediated cancer immunosurveillance (Q35140082) (← links)
- Present and Future of Allogeneic Natural Killer Cell Therapy (Q35677351) (← links)
- Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia (Q35750934) (← links)
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. (Q35753251) (← links)
- PDL1 expression is an independent prognostic factor in localized GIST. (Q35798839) (← links)
- Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway (Q35925485) (← links)
- CD117+ Dendritic and Mast Cells Are Dependent on RasGRP4 to Function as Accessory Cells for Optimal Natural Killer Cell-Mediated Responses to Lipopolysaccharide (Q35959528) (← links)
- Close encounters of different kinds: dendritic cells and NK cells take centre stage (Q36028182) (← links)
- Exploiting antitumor immunity to overcome relapse and improve remission duration (Q36044604) (← links)
- Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. (Q36057449) (← links)
- Silencing c-Kit expression in human DCs suppresses Th2, Th17 response but enhances Th1 response (Q36225816) (← links)
- Effects of imatinib on normal hematopoiesis and immune activation. (Q36248539) (← links)
- Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines (Q36261782) (← links)
- Natural killer cell-dendritic cell crosstalk in the initiation of immune responses (Q36269618) (← links)
- CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner (Q36403637) (← links)
- Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity (Q36490747) (← links)
- The anticancer immune response: indispensable for therapeutic success? (Q36677608) (← links)
- Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate (Q36694926) (← links)
- Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome (Q36694931) (← links)
- Harnessing the immune system to treat cancer (Q36809755) (← links)
- Signaling of c-kit in dendritic cells influences adaptive immunity (Q36811035) (← links)
- Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib (Q36866959) (← links)
- Emerging functions of c-kit and its ligand stem cell factor in dendritic cells: regulators of T cell differentiation (Q36959863) (← links)
- Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors (Q36965879) (← links)
- The 'kiss of death' by dendritic cells to cancer cells (Q36975757) (← links)
- Immunological aspects of cancer chemotherapy (Q37039588) (← links)